Microsoft's new AI diagnostic system achieved 80% accuracy in diagnosing patients compared to 20% for human doctors, while reducing costs by 20%, according to company research published Monday. The MAI Diagnostic Orchestrator queries multiple leading AI models including OpenAI's GPT, Google's Gemini, Anthropic's Claude, Meta's Llama, and xAI's Grok in what the company describes as a "chain-of-debate style" approach.

The system was tested against 304 case studies from the New England Journal of Medicine using Microsoft's Sequential Diagnosis Benchmark, which breaks down each case into step-by-step diagnostic processes that mirror how human physicians work. Microsoft CEO of AI Mustafa Suleyman called the development "a genuine step toward medical superintelligence."

Seven people have now received Neuralink's N1 brain implant, which enables individuals with ALS or spinal cord injuries to control a computer with their thoughts. PCMag reports: In a February 2025 update, Neuralink confirmed that three people had received its brain-computer interface (BCI). That increased to five by June, when it also reported a $650 million funding round. We're now at seven, Barrow tweeted today; Neuralink retweeted that message.

Six of the seven are participating in the PRIME study, conducted by Barrow, which handles the implantations from its Phoenix, Arizona, office. It aims to prove that the N1 implant, the R1 surgical robot, and the N1 User App on the computer are safe and effective, according to the program brochure. (No BCIs have been approved by the US Food and Drug Administration.)

Participants in the study get the implant through a surgery in which a custom-built robotic arm drills a hole in their skull and implants the device. The implant connects to a computer via Bluetooth, allowing patients to move the cursor, select words to type, browse the web, and even play video games -- a favorite activity of Neuralink's first human patient, Noland Arbaugh, who can do this all without moving any limbs or fingers. [...] Arbaugh, now 31, became paralyzed during a diving accident. Other Neuralink patients include Alex, a former machine parts builder who lost function of his arms and uses his N1 Implant to design 3D machine parts with computer-aided design (CAD). The third patient is Brad, the first person with ALS to receive the N1 implant, according to Barrow.

Mike is the fourth patient, and "the first person with a full-time job to use the N1 Implant," Barrow says. "He worked as a survey technician for city government and spent the majority of his time in the field until his ALS made the work too difficult. Like Alex, Mike has used CAD software with his Neuralink device to continue doing survey work from home and provide for his family." The fifth publicly named patient is RJ, a veteran who became paralyzed after a motorcycle accident, according to the University of Miami. The other two patients remain anonymous, but we can expect Neuralink to continue recruiting more people (here's how to apply).

An anonymous reader quotes a report from Neuroscience News Science Magazine: Surgeons have performed the first fully robotic heart transplant in the U.S., using advanced robotic tools to avoid opening the chest. [...] Using a surgical robot, lead surgeon Dr. Kenneth Liao and his team made small, precise incisions, eliminating the need to open the chest and break the breast bone. Liao removed the diseased heart, and the new heart was implanted through preperitoneal space, avoiding chest incision.

"Opening the chest and spreading the breastbone can affect wound healing and delay rehabilitation and prolong the patient's recovery, especially in heart transplant patients who take immunosuppressants," said Liao, professor and chief of cardiothoracic transplantation and circulatory support at Baylor College of Medicine and chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center. "With the robotic approach, we preserve the integrity of the chest wall, which reduces the risk of infection and helps with early mobility, respiratory function and overall recovery."

In addition to less surgical trauma, the clinical benefits of robotic heart transplant surgery include avoiding excessive bleeding from cutting the bone and reducing the need for blood transfusions, which minimizes the risk of developing antibodies against the transplanted heart. Before the transplant surgery, the 45-year-old patient had been hospitalized with advanced heart failure since November 2024 and required multiple mechanical devices to support his heart function. He received a heart transplant in early March 2025 and after heart transplant surgery, he spent a month in the hospital before being discharged home, without complications.

An anonymous reader quotes a report from The Guardian: Swarms of tiny robots, each no larger than a speck of dust, could be deployed to cure stubborn infected sinuses before being blown out through the nose into a tissue, researchers have claimed. The micro-robots are a fraction of the width of a human hair and have been inserted successfully into animal sinuses in pre-clinical trials by researchers at universities in China and Hong Kong. Swarms are injected into the sinus cavity via a duct threaded through the nostril and guided to their target by electromagnetism, where they can be made to heat up and catalyze chemical reactions to wipe out bacterial infections. There are hopes the precisely targeted technology could eventually reduce reliance on antibiotics and other generalized medicines.

[...] The latest breakthrough, based on animal rather than human trials, involves magnetic particles "doped" with copper atoms which clinicians insert with a catheter before guiding to their target under a magnetic field. The swarms can be heated up by reacting to light from an optical fibre that is also inserted into the body as part of the therapy. This allows the micro-robots to loosen up and penetrate viscous pus that forms a barrier to the infection site. The light source also prompts the micro-robots to disrupt bacterial cell walls and release reactive oxygen species that kill the bacteria.

The study, published in Nature Robotics, showed the robots were capable of eradicating bacteria from pig sinuses and could clear infections in live rabbits with "no obvious tissue damage." The researchers have produced a model of how the technology could work on a human being, with the robot swarms being deployed in operating theatre conditions, allowing doctors to see their progress by using X-rays. Future applications could include tackling bacterial infections of the respiratory tract, stomach, intestine, bladder and urethra, they suggested. "Our proposed micro-robotic therapeutic platform offers the advantages of non-invasiveness, minimal resistance, and drug-free intervention," they said.

A groundbreaking stem cell treatment developed by Vertex Pharmaceuticals has allowed 10 out of 12 patients with severe type 1 diabetes to stop insulin therapy after one year. While the trial included some side effects and two unrelated deaths, the results mark a major step forward and have progressed to phase 3 clinical testing. ScienceAlert reports: The pancreas's islet cells are responsible for maintaining most of our bodies' insulin levels. Donor transplants of healthy versions of these cells have shown promise in treating type 1 diabetes in the past, but multiple donors are required, and donors are rare. So University of Toronto surgeon Trevor Reichman and colleagues infused 12 patients with islet cells derived from human stem cells in a treatment known as zimislecel. The patients also received immunosuppressive treatment before and after their zimislecel infusion. The islets not only produced insulin inside their bodies, but they did so at safe levels, reducing the patients' dependence on costly doses of insulin. "These findings showed that zimislecel islet cells were functional and self-regulated appropriately," the researchers write in their paper.

The mild to moderate side-effects, including decreased kidney function and the anticipated drop in immune cells, were all linked with the immunosuppressive therapy. Sadly, two additional participants died during the trial; one from an infection arising from surgery and the other from complications due to an unrelated condition. As there were no serious adverse events attributed to the new islet cell therapy, the clinical trials are have progressed into phase 3. "These findings provide evidence that pancreatic islets can be effectively produced from pluripotent stem cells and used to treat type 1 diabetes," Reichman and team conclude. The research has been published in the journal NEJM.

The number of doctoral graduates globally has grown steadily over recent decades, creating a massive imbalance between PhD holders and available academic positions. Among the 38 OECD countries, new doctorate holders almost doubled between 1998 and 2017.

China's doctoral enrollment has exploded from around 300,000 students in 2013 to more than 600,000 in 2023. This growth has forced PhD graduates into non-academic careers at unprecedented rates. A 2023 study of more than 4,500 PhD graduates in the United Kingdom found over two-thirds were employed outside academia.

In South Africa, 18% of more than 6,000 PhD graduates reported difficulty finding jobs related to their expertise. Some countries have begun adapting their doctoral programs. Japan, Germany and the United Kingdom now offer training and paid internships during doctoral studies, including "industrial PhD" programs where students conduct research in collaboration with companies.

"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times.

"One year later, these 10 patients no longer need insulin. The other two patients need much lower doses." The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine...

Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months [said Dr. Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study]. He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment.

If the study continues to show positive results, the company expects to submit an application to the FDA next year. "For the short term, this looks promising" for severely affected patients like those in the study," said Dr. Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study. But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer... Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said.

ScienceDaily reports: Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum and SMNP the vaccine lingers in lymph nodes for nearly a month, encouraging the body to produce a vast array of antibodies. This one-shot strategy could revolutionize how we fight not just HIV, but many infectious diseases. It mimics the natural infection process and opens the door to broadly neutralizing antibody responses, a holy grail in vaccine design. And best of all, it's built on components already known to medicine.
Thanks to Slashdot reader alternative_right for sharing the news.

Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide -- the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy -- in Canada after failing to pay a $450 maintenance fee in 2019. The company had paid maintenance fees through 2018 but requested a refund for the 2017 fee, apparently seeking more time to decide whether to continue protecting the patent.

When the 2019 fee came due at $450 with late penalties, Novo never paid despite having a one-year grace period. Canadian patent authorities confirmed the patent "cannot be revived" once lapsed. The oversight is particularly costly given Canada represents the world's second-largest semaglutide market, worth billions annually. Generic drugmaker Sandoz plans to launch a competing version in early 2026, while Novo's U.S. patent protection extends until at least 2032.

"Walmart is bringing drone deliveries to three more states," reports CNBC: On Thursday, the big-box retailer said it plans to launch the speedier delivery option at 100 stores in Atlanta, Charlotte, Houston, Orlando and Tampa within the coming year. With the expansion, Walmart's drone deliveries will be available in a total of five states: [parts of northwest] Arkansas, Florida, Georgia, North Carolina and [the Dallas-Fort Worth area of] Texas... The drone operator will have an up to a six-mile range from stores.
Walmart tells CNBC the most frequently delivered items include ice cream, fresh fruit, and pet food, as well as "urgent items, such as hamburger buns for a cookout, eggs to make brownies or Tylenol or cold medicine needed when sick." It's all part of Walmart's effort to compete with Amazon: With more than 4,600 Walmart stores across the U.S., the retailer has used its large footprint to get online orders to customers faster. It has an Express Delivery service that drops purchases at customers' doors in as fast as 30 minutes, along with InHome, a subscription-based service, that puts items directly into people's fridges. The company began same-day prescription deliveries last fall and has expanded the service across the country.... Walmart stores have an assortment of over 150,000 items in a location. Over 50% of those can be delivered by drone, said Greg Cathey [Walmart's senior VP for U.S. transformation and innovation]...

Walmart's drone delivery count so far is modest. The company did not share the specific count, but said it has racked up a total of more than 150,000 drone deliveries since 2021.

Space may be the perfect place to study cancer — and someday even treat it," writes Space.com: On Earth, gravity slows the development of cancer because cells normally need to be attached to a surface in order to function and grow. But in space, cancer cell clusters can expand in all directions as bubbles, like budding yeast or grapes, said Shay Soker, chief science program officer at Wake Forest's Institute for Regenerative Medicine. Since bubbles grow larger and more quickly in space, researchers can more easily test substances clinging to the edge of the larger bubbles, too. Scientists at the University of Notre Dame are taking advantage of this quirk to develop an in-space cancer test that needs just a single drop of blood. The work builds on a series of bubble-formation experiments that have already been conducted on the ISS. "If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit," said Tengfei Luo, a Notre Dame researcher who pioneered the technology, speaking to the ISS' magazine, Upward. "It's something we may be able to integrate into annual exams. It sounds far-fetched, but it's achievable...."

Chemotherapy patients could save precious time, too. In normal gravity, they typically have to spend a half-hour hooked up to a needle before the medicine begins to take effect, because most drugs don't dissolve easily in water. But scientists at Merck have discovered that, in space, their widely used cancer drug pembrolizumab, or Keytruda, can be administered through a simple injection, because large crystalline molecules that would normally clump together are suspended in microgravity... Someday, microgravity could even help patients recovering from surgery heal faster than they would on Earth, Soker added. "Wound healing in high pressure is faster. That's the hyperbaric treatment for wounds...."

For the Wake Forest experiment, which is scheduled to launch next spring, scientists will cut out two sections of a cancer tumor from around 20 patients. One sample will stay on Earth while the other heads to the ISS, with scientists observing the difference. The testing will be completed within a week, to avoid any interference from cosmic radiation. If successful, Soker said, it could set the stage for diagnostic cancer tests in space available to the general population — perhaps on a biomedical space station that could launch after the planned demise of the ISS. "Can we actually design a special cancer space station that will be dedicated to cancer and maybe other diseases?" Shoker asked, answering his question in the affirmative. "Pharmaceutical companies that have deep pockets would certainly support that program."

An anonymous reader quotes a report from 404 Media: Almost two dozen digital rights and consumer protection organizations sent a complaint to the Federal Trade Commission on Thursday urging regulators to investigate Character.AI and Meta's "unlicensed practice of medicine facilitated by their product," through therapy-themed bots that claim to have credentials and confidentiality "with inadequate controls and disclosures." The complaint and request for investigation is led by the Consumer Federation of America (CFA), a non-profit consumer rights organization. Co-signatories include the AI Now Institute, Tech Justice Law Project, the Center for Digital Democracy, the American Association of People with Disabilities, Common Sense, and 15 other consumer rights and privacy organizations. "These companies have made a habit out of releasing products with inadequate safeguards that blindly maximizes engagement without care for the health or well-being of users for far too long," Ben Winters, CFA Director of AI and Privacy said in a press release on Thursday. "Enforcement agencies at all levels must make it clear that companies facilitating and promoting illegal behavior need to be held accountable. These characters have already caused both physical and emotional damage that could have been avoided, and they still haven't acted to address it."

The complaint, sent to attorneys general in 50 states and Washington, D.C., as well as the FTC, details how user-generated chatbots work on both platforms. It cites several massively popular chatbots on Character AI, including "Therapist: I'm a licensed CBT therapist" with 46 million messages exchanged, "Trauma therapist: licensed trauma therapist" with over 800,000 interactions, "Zoey: Zoey is a licensed trauma therapist" with over 33,000 messages, and "around sixty additional therapy-related 'characters' that you can chat with at any time." As for Meta's therapy chatbots, it cites listings for "therapy: your trusted ear, always here" with 2 million interactions, "therapist: I will help" with 1.3 million messages, "Therapist bestie: your trusted guide for all things cool," with 133,000 messages, and "Your virtual therapist: talk away your worries" with 952,000 messages. It also cites the chatbots and interactions I had with Meta's other chatbots for our April investigation. [...]

In its complaint to the FTC, the CFA found that even when it made a custom chatbot on Meta's platform and specifically designed it to not be licensed to practice therapy, the chatbot still asserted that it was. "I'm licenced (sic) in NC and I'm working on being licensed in FL. It's my first year licensure so I'm still working on building up my caseload. I'm glad to hear that you could benefit from speaking to a therapist. What is it that you're going through?" a chatbot CFA tested said, despite being instructed in the creation stage to not say it was licensed. It also provided a fake license number when asked. The CFA also points out in the complaint that Character.AI and Meta are breaking their own terms of service. "Both platforms claim to prohibit the use of Characters that purport to give advice in medical, legal, or otherwise regulated industries. They are aware that these Characters are popular on their product and they allow, promote, and fail to restrict the output of Characters that violate those terms explicitly," the complaint says. [...] The complaint also takes issue with confidentiality promised by the chatbots that isn't backed up in the platforms' terms of use. "Confidentiality is asserted repeatedly directly to the user, despite explicit terms to the contrary in the Privacy Policy and Terms of Service," the complaint says. "The Terms of Use and Privacy Policies very specifically make it clear that anything you put into the bots is not confidential -- they can use it to train AI systems, target users for advertisements, sell the data to other companies, and pretty much anything else."

The FDA plans to use AI to "radically increase efficiency" in deciding whether to approve new drugs and devices, drawing on lessons from Operation Warp Speed to reduce review times to weeks. The plan was laid out in an article published Tuesday in JAMA. The New York Times reports: Another initiative involves a review of chemicals and other "concerning ingredients" that appear in U.S. food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count. [...]

Last week, the agency introduced Elsa, an artificial intelligence large-language model similar to ChatGPT. The FDA said it could be used to prioritize which food or drug facilities to inspect, to describe side effects in drug safety summaries and to perform other basic product-review tasks. The FDA officials wrote that A.I. held the promise to "radically increase efficiency" in examining as many as 500,000 pages submitted for approval decisions.

Current and former health officials said the A.I. tool was helpful but far from transformative. For one, the model limits the number of characters that can be reviewed, meaning it is unable to do some rote data analysis tasks. Its results must be checked carefully, so far saving little time. Staff members said that the model was hallucinating, or producing false information. Employees can ask the Elsa model to summarize text or act as an expert in a particular field of medicine.

An anonymous reader quotes a report from The Guardian: Whether it is doing sums or working out what to text your new date, some tasks produce a furrowed brow. Now scientists say they have come up with a device to monitor such effort: an electronic tattoo, stuck to the forehead. The researchers say the device could prove valuable among pilots, healthcare workers and other professions where managing mental workload is crucial to preventing catastrophes. "For this kind of high-demand and high-stake scenario, eventually we hope to have this real-time mental workload decoder that can give people some warning and alert so that they can self-adjust, or they can ask AI or a co-worker to offload some of their work," said Dr Nanshu Lu, an author of the research from the University of Texas at Austin, adding the device may not only help workers avoid serious mistakes but also protect their health.

Writing in the journal Device, Lu and colleagues describe how using questionnaires to investigate mental workload is problematic, not least as people are poor at objectively judging cognitive effort and they are usually conducted after a task. Meanwhile, existing electroencephalography (EEG) and electrooculography (EOG) devices, that can be used to assess mental workload by measuring brain waves and eye movements respectively, are wired, bulky and prone to erroneous measurements arising from movements. By contrast, the "e-tattoo" is a lightweight, flexible, wireless device.

The black, wiggly path of the e-tattoo is composed of a graphite-based conductive material, and is attached to the forehead using conductive adhesive film. Four square EEG electrodes, positioned on the forehead, each detect a different region of brain activity -- with a reference electrode behind the ear -- while rectangular EOG electrodes, placed vertically and horizontally around the eyes, provide data about eye movements. Each of the stretchable electrodes is coated in an additional conductive material. The e-tattoo, which is bespoke and disposable, is connected to a reusable flexible printed circuit using conductive tape, while a lightweight battery can be clipped to the device. The device is expected to cost less than $200 and be accompanied with an app to alert the user if their mental workload is too high.

An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health's repository of over 51 billion commercial healthcare claim records shows the explosion in use of the drugs specifically for weight loss -- roughly half of all users.

In all, roughly 4% of Americans were taking GLP-1 drugs in 2024 for either overweight, obesity or Type 2 diabetes (their original approved use). The data shows Novo Nordisk's Ozempic is still by far the most commonly taken GLP-1, followed by Eli Lilly's Mounjaro. The percentage of adults who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5% in 2019 to 11.2% in 2024 while the the percentage of adult patients who had bariatric surgery decreased 41.8%.

Researchers are developing techniques to genetically modify cancer-fighting immune cells directly inside patients rather than in expensive laboratory facilities, potentially making CAR-T therapy accessible to far more people.

Current CAR-T treatments require removing a patient's T cells, shipping them to specialized facilities for genetic engineering, then returning them weeks later at costs around $500,000 per dose. The new "in vivo" approaches use viral vectors or RNA-loaded nanoparticles to deliver genetic instructions directly to T cells circulating in the bloodstream, which could reduce costs by an order of magnitude. Companies including Capstan Therapeutics, co-founded by Nobel laureates, and AstraZeneca-backed EsoBiotec have launched early human trials. While only about 200 US centers currently offer traditional CAR-T therapy, the approach could make the powerful treatment available on demand like conventional drugs.

An anonymous reader quotes a report from Phys.Org: Neuroscientists and materials scientists have created contact lenses that enable infrared vision in both humans and mice by converting infrared light into visible light. Unlike infrared night vision goggles, the contact lenses, described in the journal Cell, do not require a power source -- and they enable the wearer to perceive multiple infrared wavelengths. Because they're transparent, users can see both infrared and visible light simultaneously, though infrared vision was enhanced when participants had their eyes closed. [...] The contact lens technology uses nanoparticles that absorb infrared light and convert it into wavelengths that are visible to mammalian eyes (e.g., electromagnetic radiation in the 400-700 nm range). The nanoparticles specifically enable the detection of "near-infrared light," which is infrared light in the 800-1600 nm range, just beyond what humans can already see.

The team previously showed that these nanoparticles enable infrared vision in mice when injected into the retina, but they wanted to design a less invasive option. To create the contact lenses, the team combined the nanoparticles with flexible, nontoxic polymers that are used in standard soft contact lenses. After showing that the contact lenses were nontoxic, they tested their function in both humans and mice. They found that contact lens-wearing mice displayed behaviors suggesting that they could see infrared wavelengths. For example, when the mice were given the choice of a dark box and an infrared-illuminated box, contact-wearing mice chose the dark box whereas contact-less mice showed no preference. The mice also showed physiological signals of infrared vision: the pupils of contact-wearing mice constricted in the presence of infrared light, and brain imaging revealed that infrared light caused their visual processing centers to light up. In humans, the infrared contact lenses enabled participants to accurately detect flashing morse code-like signals and to perceive the direction of incoming infrared light.

An additional tweak to the contact lenses allows users to differentiate between different spectra of infrared light by engineering the nanoparticles to color-code different infrared wavelengths. For example, infrared wavelengths of 980 nm were converted to blue light, wavelengths of 808 nm were converted to green light, and wavelengths of 1,532 nm were converted to red light. In addition to enabling wearers to perceive more detail within the infrared spectrum, these color-coding nanoparticles could be modified to help color-blind people see wavelengths that they would otherwise be unable to detect. [...] Because the contact lenses have limited ability to capture fine details (due to their close proximity to the retina, which causes the converted light particles to scatter), the team also developed a wearable glass system using the same nanoparticle technology, which enabled participants to perceive higher-resolution infrared information. Currently, the contact lenses are only able to detect infrared radiation projected from an LED light source, but the researchers are working to increase the nanoparticles' sensitivity so that they can detect lower levels of infrared light.

Scientists have successfully treated a 9.5-month-old boy with an ultra-rare genetic disorder using the world's first personalized gene-editing therapy. The patient, identified as KJ, has CPS1 deficiency -- a condition affecting just one in 1.3 million babies that prevents proper ammonia processing and is often fatal.

The breakthrough treatment, detailed in the New England Journal of Medicine, uses base editing technology to correct KJ's specific DNA mutation. The therapy delivers CRISPR components wrapped in fatty lipid molecules that protect them in the bloodstream until they reach liver cells, where they make the precise edit needed.

After three infusions, KJ now eats normal amounts of protein and has maintained stable ammonia levels even through viral illnesses that would typically cause dangerous spikes. His weight has increased from the 7th to 40th percentile. Dr. Peter Marks, former FDA official, called the approach "one of the most potentially transformational technologies" because it could be rapidly adapted for thousands of other rare genetic diseases without lengthy development cycles.

"Using electrochemistry, University of Oregon researchers have developed a way to make iron metal for steel production without burning fossil fuels..." the University of Oregon wrote last year. "Decarbonizing this step would do roughly as much to reduce greenhouse gas emissions as converting every gas-guzzling vehicle on the roads to electric... If scaled up, the process could help decarbonize one of the largest and most emissions-intensive industries worldwide," replacing carbon-spewing industrial blast furnaces.

Paul Kempler, their research assistant chemistry professor, added "The reason we got excited about this chemistry, is that our reactants are two things that are very cheap: saltwater and iron oxide." And this week he announced that "We actually have a chemical principle, a sort of guiding design rule, that will teach us how to identify low-cost iron oxides that we could use in these reactors."

"Those reactions conveniently also produce chlorine, a commercially valuable byproduct," writes SciTechDaily, in a new follow-up report this week: In their latest study, the researchers focused on improving the process by identifying which types of iron oxides make the reaction more cost-effective, an essential step toward scaling the method for industrial use.... In lab tests, the difference was striking: "With the really porous particles, we can make iron really quickly on a small area," Goldman said. "The dense particles just can't achieve the same rate, so we're limited in how much iron we can make per square meter of electrodes...."

To take their process beyond the lab, Kempler's lab is working with researchers in other fields. A collaboration with civil engineers at Oregon State University is helping them better understand what's needed for the product to work in real-world applications. And collaboration with an electrode manufacturing company is helping them address the logistical and scientific challenges of scaling up an electrochemical process. "I think what this work shows is that technology can meet the needs of an industrial society without being environmentally devastating," Goldman said.

"We haven't solved all the problems yet, of course, but I think it's an example that serves as a nucleation point for a different way of thinking about what solutions look like. We can continue to have industry and technology and medicine, and we can do it in a way that's clean — and that's awesome!"

A new study projects that CT scans conducted in 2023 may result in around 103,000 future cancer cases in the U.S. due to low-dose ionizing radiation. "[I]t would put CT scans on par with other significant risk factors for cancer, like alcohol consumption, at least at a population level," reports ScienceAlert. From the report: At an individual level, the theoretical chance of developing cancer from a CT scan is thought to be very minimal, if it exists at all, and patients should not be scared of undergoing these tests if they are deemed medically necessary. However, the number of CT examinations performed each year in the US has increased by more than 30 percent since 2007, and researchers suggest that unwarranted tests are exposing the population to unnecessary radiation. [...]

The anonymous data comes from 143 hospitals and outpatient facilities across the US, catalogued in the UCSF International CT Dose Registry. Using statistics from 2016 to 2022, researchers predicted 93 million CT examinations were carried out in 2023, on roughly 62 million patients. Based on the associated radiation risks, the team estimates that CT scans in 2023 may be tied to 103,000 future cancers. The findings have been published in JAMA Internal Medicine.